Molecules in prostate tumors might predict whether RT can help prevent recurrence

(Press-News.org) COLUMBUS, Ohio - A new study has identified a group of molecules in prostate-cancer cells that doctors might one day use to distinguish which patients should be treated with radiation therapy if rising PSA levels indicate their cancer has recurred after surgical removal of the prostate. Led by researchers at the Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC - James), the retrospective study suggested that a pattern of molecules called microRNA (miRNA) in tumor cells might predict patients' response to radiation therapy . In particular, the study suggests that two miRNAs - miR-4516 and miR-601 - in tumor cells along with Gleason score and lymph node status may help identify patients who might experience rising PSA after they've been treated with radiation therapy. "This study is the first to demonstrate that miRNA expression in tumor cells correlates with outcome after salvage radiation therapy, paving the way for the potential use of miRNA biomarkers in prostate cancer treatment," says first author Erica Hlavin Bell, PhD, assistant professor-clinical in radiation oncology. In addition, the researchers correlated a pattern of 88 miRNAs with tumors that first recurred early after prostatectomy - within three years or less - versus tumors that recurred after three years. The findings are published in the journal PLOS ONE. "If validated by further studies, these findings could change clinical practice and improve the care of prostate-cancer patients," says study leader Arnab Chakravarti, MD, chair and professor of Radiation Oncology and director of Ohio State's Brain Tumor Program. "Men found to have aggressive disease at the time of prostatectomy could be offered additional treatment with radiation therapy to prevent recurrence, while sparing men with slow-growing tumors," adds Chakravarti, who holds the Max Morehouse Chair of Cancer Research. "These findings are important because it is currently hard to distinguish early which patients will benefit from radiation therapy following radical prostatectomy and which will receive no benefit," says Bell. "Our novel miRNA panel might also shed light on the underlying mechanisms of treatment resistance in prostate cancer." Prostate cancer is the most frequently diagnosed cancer in men. An estimated 220,800 new cases are expected in the United States in 2015, along with 27,540 deaths from recurrent disease. Currently, rising blood levels of prostate-specific antigen (PSA), a protein made by the prostate gland, are used as indicators of tumor recurrence. Removal of the prostate is widely used to treat men with early-stage disease. But up to 30 to 40 percent of these patients experience rising PSA levels after surgery, and these patients are often treated using radiation therapy. This study analyzed preserved tumor samples from 43 prostate cancer patients who later received radiation therapy after rising PSA levels were detected following a radical prostatectomy. The study's key findings include: A new model for recurrence based on rising PSA levels was developed; the model is based on miR-4561 and miR-601, together with Gleason score and lymph node status; The model significantly improved prediction of response to radiation therapy over the use of Gleason score and lymph-node status alone; 88 miRNAs were associated with time to first recurrence after a radical prostatectomy.

INFORMATION:

Other researchers involved in this study were Jessica L. Fleming, Xiaokui Mo, Stella Ling, Denise Fabian, Isabel Manring, Maureen McNulty, Debra L. Zynger, Douglas Martin and Julia White, The Ohio State University; Simon Kirste, Petra Stegmaier, Vanessa Drendel, Cordula A. Jilg, Wolfgang Schultze-Seemann, Martin Werner and Anca L. Grosu, University Medical Center Freiburg, Freiburg, Germany. The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute strives to create a cancer-free world by integrating scientific research with excellence in education and patient-centered care, a strategy that leads to better methods of prevention, detection and treatment. Ohio State is one of only 41 National Cancer Institute (NCI)-designated Comprehensive Cancer Centers and one of only four centers funded by the NCI to conduct both phase I and phase II clinical trials. The NCI recently rated Ohio State's cancer program as "exceptional," the highest rating given by NCI survey teams. As the cancer program's 228-bed adult patient-care component, The James is a "Top Hospital" as named by the Leapfrog Group and one of the top cancer hospitals in the nation as ranked by U.S.News & World Report.